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Abstract
Background and Aims: The FibroTest (FT) demonstrated excellent diagnostic performance in the prediction of liver fibrosis
in patients with chronic hepatitis B (CHB). Here, we aimed to identify predictors of discordance between FT and liver biopsy
(LB) in Asian patients with CHB.
Methods: Consecutive patients with CHB who underwent both LB and FT on the same day between 2007 and 2010 were
recruited from three medical institutes. Laboratory evaluations including specific parameters for calculating FT score, such
as a2-macroglobulin, apolipoprotein A1, haptoglobin, c-glutamyl transpeptidase, and total bilirubin levels, were obtained.
The Batts and Ludwig scoring system was used for histological analysis.
Results: A total of 330 patients (200 male and 130 female) were analyzed. Discordances of at least two fibrosis stages
between FT and LB were observed in 30 (9.1%) patients; using FT, fibrosis was underestimated in 25 patients and
overestimated in 5 patients with reference to LB. Patients with discordance had a higher proportion of F3–4 (P,0.001) and
F4 (P= 0.012) compared with those with nondiscordance. The discordance rate was significantly higher in those with F3–4
than those with F1–2 (15.4% vs. 3.0%, P,0.001). Multivariate analysis demonstrated F3–4 at LB as the only independent
factor for discordance (P,0.001; odds ratio 5.95). After adjusting fibrosis stages, neither necroinflammatory activity on
histology nor serum ALT level influenced FT values independently.
Conclusion: Advanced fibrosis stage (F3–4) is the sole factor of discordance between FT and LB in Asian patients with CHB.
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Introduction
Accurate assessment of the severity of liver fibrosis in patients
with chronic hepatitis B (CHB) is necessary not only to predict the
long-term clinical course, but also to determine whether and when
to begin antiviral therapy. To-date, liver biopsy (LB) has been the
gold standard for assessing liver fibrosis. However, it is often
limited because of its invasiveness, cost, risk of complications, poor
acceptance, lack of availability of expert practitioners, and intra/
inter-observer variability [1,2]. These factors make sequential LBs
unfeasible, especially when repeated examinations are required to
monitor the response to antiviral or anti-fibrotic treatment.
Consequently, these limitations have stimulated research into
noninvasive approaches. So far, two kinds of noninvasive
surrogates have been identified: (1) ultrasound-based methods
such as transient elastography [3,4] or acoustic radiation force
impulse (ARFI) [5], and (2) biochemical marker-based methods
such as the aspartate aminotransferase (AST)-to-platelet ratio
index (APRI) [6], AST-to-alanine aminotransferase (ALT) ratio
[7], and FibroTest (FT) (BioPredictive, Paris, France) [8], all of
which combine several biochemical parameters [9].
Of these, the FT was first proposed by Poynard et al. [8] in
2001. It is a scoring algorithm that uses a panel of five biochemical
markers, including a2-macroglobulin, apolipoprotein A1, hapto-
globin, c-glutamyl-transpeptidase (GGT), and total bilirubin to
assess liver fibrosis adjusted by age and gender. Since FT was
initially investigated in Caucasian populations with chronic
hepatitis C (CHC), its performance as a surrogate marker for LB
has been studied extensively and has shown a good correlation
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e55759
with histological liver fibrosis stage [10–12]. In addition, a recent
study reported that FT can also predict liver fibrosis with
comparable accuracy to transient elastography in Asian patients
with CHB [13].
However, such indirect methods as noninvasive surrogates for
LB, including the FT, are always subject to discordance compared
with fibrosis staging by LB. Thus, identification of factors
associated with the discordance between noninvasive surrogates
and LB may enable us to determine the optimal method among
several noninvasive tests. Furthermore, if the effects of other
clinical variables (i.e., necroinflammatory activity) on FT values
other than the fibrosis stage itself are elucidated, the optimal
timing for evaluation of the intrahepatic fibrotic burden could be
better determined, ultimately avoiding underestimation or over-
estimation of the real fibrotic burden.
However, to our knowledge, investigations of these issues are
scarce so far, especially for the FT. In this study, we aimed to
identify predictors of discordance between LB and the FT and to
investigate the potential effects of necroinflammation on FT values
in Asian patients with CHB.
Patients and Methods
Patients
Consecutive patients with CHB who underwent both LB and
the FT on the same day at Severance Hospital, Yonsei University
College of Medicine, Seoul, Korea, Ajou University School of
Medicine, Suwon, Korea, and Hallym University College of
Medicine, Chuncheon, Korea between January 2007 and
December 2010 were considered eligible for this study. LB was
performed to assess the severity of fibrosis and inflammation prior
to treatment.
The exclusion criteria were as follows: previous history of
antiviral therapy; history of hepatocellular carcinoma treatment at
the time of LB; LB specimen shorter than 20 mm; coinfection with
human immunodeficiency virus or hepatitis C or D virus; alcohol
ingestion in excess of 40 g/day for more than 3 years; and Child-
Pugh classification of B or C.
The study was performed in accordance with the ethical
guidelines of the 1975 Declaration of Helsinki. Written informed
consent was obtained from each participant or responsible family
member after possible complications of the diagnostic procedures
had been fully explained.
Serum Biochemical Markers and FT Score Calculation
All laboratory data including specific parameters for calculating
the FT score, such as a2-macroglobulin level, apolipoprotein A1
level, haptoglobin level, c-GGT level, and total bilirubin level,
were obtained on the same day as the FT and LB. BioPredictive
kindly provided the complimentary service for calculation of FT
score. The discriminant cutoff values for fibrosis stage as estimated
by the FT were based on a previous study (F1, FT ,0.32; F2,
0.32# FT ,0.52; F3, 0.52# FT ,0.68; F4, FT $0.68) [13].
Liver Biopsy Examination
Percutaneous LB was performed using a 16G disposable needle.
The LB specimens were fixed in formalin and embedded in
paraffin. Sections 4 mm thick were then stained with hematoxylin
and eosin and Masson’s trichrome. All liver tissue samples were
evaluated by an experienced hepatopathologist in each institute
blinded to the patients’ clinical histories. Specimens that were
shorter than 17 mm and considered by the pathologists to be
unsuitable for fibrosis assessment were excluded from the analysis.
Liver histology was evaluated semiquantitatively according to the
Batts and Ludwig scoring system [14]. Fibrosis was staged on a 0–
4 scale: F0, no fibrosis; F1, portal fibrosis; F2, periportal fibrosis;
F3, septal fibrosis; and F4, cirrhosis. Significant fibrosis was
defined as F2 or more, advanced fibrosis as F3 or more, and
cirrhosis as F4.
Statistical Analysis
Continuous variables of patients with discordance and those
without were compared with independent t-tests or Mann-
Whitney U tests, as appropriate. The chi-squared or Fisher’s
exact tests were used for categorical variables. Based on previous
studies [15–17], discordance was defined as a discordance of at
least two stages between fibrosis stages determined by the FT and
LB. Subsequent multivariate analysis using binary logistic re-
gression analyses was performed to identify independent factors
related to discordance between fibrosis stage of the FT and LB.
Odds ratios (ORs) and corresponding 95% confidence intervals
(CIs) were also indicated.
Statistical analyses were performed using the SPSS software
(ver. 18.0; SPSS Inc., Chicago, IL, USA). In all analyses, a value of
P,0.05 was taken to indicate statistical significance.
Results
Baseline Characteristics of the Study Population
A total of 628 consecutive patients were screened for possible
inclusion in the study. Based on the above exclusion criteria, a total
of 330 patients (200 male and 130 female) were finally analyzed
(Figure 1).
Baseline characteristics of study cohort are summarized in
Table 1. The median age was 44 years, and male gender
predominated (n = 200, 60.6%). The median AST and ALT levels
were 42 IU/L (range, 12–385) and 51 IU/L (range, 5–551),
respectively. All patients had well-preserved liver functions with
Child-Pugh class A.
Liver Histology and Corresponding FT Values
The median length of LB samples was 22 mm (range, 20–25).
The distribution of FT values according to maximal inflammatory
activity in each fibrosis stage is shown in Table 2. The mean FT
values increased significantly as fibrosis stage increased (0.2360.17
for F1, 0.3560.18 for F2, 0.5960.21 for F3, and 0.7160.21 for
F4; all P,0.001 between each fibrosis stage) (Table 2 and
Figure 2).
Using discriminant cutoff values to predict each fibrosis state
(F1, F2, F3, and F4) by the FT (values were suggested in a previous
study [13]), a discordance of at least two stages (gray) between the
Figure 1. Flow chart describing the selection of the study
population. CHB; Chronic hepatitis B, HCC; hepatocellular carcinoma.
doi:10.1371/journal.pone.0055759.g001
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FT and LB was observed in 30 (9.1%) patients (Table 3). On the
whole, using the FT, fibrosis stage was underestimated in 25
patients and overestimated in 5 patients with reference to LB
(Table 3).
Factors Affecting the Discordance between Histology
and FT Values
When we compared baseline characteristics of patients with
nondiscordance and those with discordance, patients with
discordance had a higher proportion of F3–4 (P,0.001) and F4
(P=0.012) than those with nondiscordance, with statistical
significance (Table 4). The discordance rate was significantly
higher in patients with F3–4 than in those with F1–2 (15.4% vs.
3.0%, respectively; P,0.001) (Figure 3).
Subsequent multivariate analysis demonstrated that F3–4 at the
time of LB was selected as the only independent factor for
discordance between the two tests showing a positive correlation
(P,0.001; adjusted OR, 5.95; 95% CI 2.22–15.96) (Table 5).
Influence of Histological Necroinflammation and ALT
Level on FT Values
Although significant differences in necroinflammatory activity
and serum ALT level between patients with discordance and those
with nondiscordance were not detected (Table 4), previous studies
of ultrasound-based tests such as transient elastography and ARFI
[5,16,18] reported overestimation of fibrosis due to secondary
effects of high ALT levels and/or necroinflammation. Thus, we
further analyzed the influence of histological necroinflammation
and ALT level in our cohort.
FT values between patients with maximal activity of grades 1–2
and 3–4 were statistically equivalent in each fibrosis stage (all
P.0.05, Figure 4). In addition, there was no significant difference
in FibroTest value between patients with normal ALT and those
with high ALT in each fibrosis stage (all P.0.05, Figure 5).
Factors Affecting Discordance Based on External Cutoff
Values
When we used the external cutoff values from BioPredictive
(0.49, 0.59, and 0.75 for F $2, F $3, and F .4, respectively),
discordances between the FT and LB were found in 41 (12.4%)
patients; 36 patients were underestimated using the FT, whereas
5 patients were overestimated. Similarly, a higher proportion of
patients with an advanced fibrosis stage (F3–4) were identified in
patients with discordance (P,0.001). On multivariate analysis,
advanced fibrosis stage (F3–4) was the only predictor positively
Table 1. Baseline characteristics (n = 330).
Variables Value
Demographic data
Age (years) 44 (20–83)
Male gender 200 (60.6)
Body mass index (kg/m2) 23.4 (15.1–35.8)
Obesity ($30 kg/m2) 9 (2.7)
Laboratory data
Serum albumin (g/dL) 4.3 (2.9–5.4)
Total bilirubin (mg/dL) 0.7 (0.2–2.0)
Aspartate aminotransferase (IU/L) 42 (12–385)
Alanine aminotransferase (IU/L) 51 (5–551)
Prothrombin time (INR) 1.1 (0.91–1.25)
Platelet count (109/L) 186 (80–489)
Values are expressed as median (range) or no. (%).
INR, international normalized ratio.
doi:10.1371/journal.pone.0055759.t001 Figure 2. Box plots of FT values according to fibrosis stage.
Mean FT values increase significantly as fibrosis stage increase (0.17 for
F1 (range, 0.02–0.92), 0.35 for F2 (range, 0.05–0.94), 0.6 for F3 (range,
0.02–0.96), and 0.76 for F4 (range, 0.2–0.99), all P,0.001 among fibrosis
stages).
doi:10.1371/journal.pone.0055759.g002
Table 2. Liver histology and corresponding FT values
(n = 330).
Fibrosis FT value*
Maximal
activitya FT value*
Stage no. (%) Mean 6 SD Grade no. Mean 6 SD
1 65 (19.7) 0.2360.17 1 32 0.2260.18
2 26 0.2460.18
3 6 0.2160.11
4 1 0.07
2 103 (31.2) 0.3560.18 1 11 0.3560.15
2 51 0.3260.18
3 27 0.3860.19
4 14 0.4060.14
3 84 (25.5) 0.5960.21 1 6 0.4960.16
2 28 0.5860.21
3 39 0.6160.20
4 11 0.5860.24
4 78 (23.6) 0.7160.21 1 7 0.7560.24
2 53 0.7260.21
3 16 0.6860.21
4 2 0.7660.11
FT values* are described as mean 6 standard deviation.
Maximal activitya grade was defined as the higher one between lobular and
periportal activity.
doi:10.1371/journal.pone.0055759.t002
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affecting discordance between the FT and LB (P,0.001;
adjusted OR 9.31, 95% CI 3.55–24.42) (Table S1).
Discussion
The FT is known to show good diagnostic performance with
reference to fibrosis stages of LB in not only the Caucasian
population with CHC, but also Asian patients with CHB [10–
13]. However, noninvasive surrogates for LB including the FT,
no matter how they achieve their excellent diagnostic perfor-
mance, are inherently subject to discordance compared with the
fibrosis staging by LB primarily because noninvasive surrogates
indirectly assess the total fibrotic burden instead of the
architectural changes in liver parenchyma, which is the major
factor in histological evaluation [19]. Nevertheless, because LB
is the current gold standard, identification of factors associated
with the discordance between noninvasive surrogates and LB is
an important prerequisite for accurate assessment of the
intrahepatic fibrotic burden. However, investigations on this
issue are scarce so far, especially for the FT. In addition, data
on the influence of necroinflammation on the FT value are
lacking, which can be an important issue for two reasons: first,
patients in whom LB is required usually have evidence of
necroinflammation along with fibrotic burden; and second,
probable effects (i.e., overestimation of fibrosis stage) of
necroinflammation have been reported for several surrogate
tests [5]. Therefore, our findings will assist formulation of
guidelines for optimal evaluation of the intrahepatic fibrotic
burden, ultimately avoiding underestimation or overestimation
of the real fibrotic burden.
To our knowledge, this is the first study to investigate the
prevalence of the discordance between LB and the FT and its
predictors in Asian patients with CHB in a relative large cohort
from three medical institutes. Advanced fibrosis (F3–4) at LB is
a sole factor attributed to discordance between fibrosis stages by
LB and the FT, indicating a greater chance of agreement
between LB and the FT when patients with CHB show F0–2 at
the time of LB. Indeed, most discordance in this study was
caused by underestimation of liver fibrosis by the FT in patients
with F3–4 (11 cases of F3 and 14 of F4 of 30 discordant cases).
Furthermore, we analyzed the additional influence of histolog-
ical necroinflammatory activity and serum ALT level on FT
values in each fibrosis stage; neither affected either the
likelihood of discordance or FT value itself. Interestingly, when
we used the external cutoff values from BioPredictive, an
advanced fibrosis stage of F3–4 was selected again as the only
predictor of discordance.
In contrast to the FT, for transient elastography, a fibrosis stage
of F0–2 is the only factor that predicts significant discordance with
reference to LB in Asian patients with CHB, and necroinflamma-
tion (i.e., serum ALT level more than twice the upper normal limit)
has been identified as a significant confounder, which non-
specifically increases liver stiffness values and thus leads to
overestimation of the fibrosis stage [15–18,20]. Therefore, with
active necroinflammation or ALT flares, measuring liver stiffness
using transient elastography should be delayed after stabilization of
necroinflammation and normalization of serum ALT to exclude
such undesirable overestimating effects [21]. Such contradictory
results of the FT and transient elastography are noteworthy in that
they might be mutually complementary in assessing liver fibrosis in
terms of combining the FT with transient elastography to enhance
the diagnostic accuracy.
However, paradoxically, a histological stage of F0–2 favoring
the use of the FT or F3–4 favoring the use of transient
elastography cannot be revealed without LB. Therefore, the
optimal diagnostic algorithm for use of these two noninvasive
surrogates remains unresolved. The French guideline for
Table 3. Distribution of fibrosis stages according to histology and FT.
Fibrosis stage estimated by histology Fibrosis stage estimated by FT
F1 F2 F3 F4
FT,0.32 0.32#FT,0.52 0.52#FT,0.68 FT$0.68
F1 (n = 65) 50 12 1 2
F2 (n = 103) 46 40 45 2
F3 (n = 84) 11 12 36 25
F4 (n = 78) 8 6 10 54
Total (n = 330) 115 70 92 83
doi:10.1371/journal.pone.0055759.t003
Figure 3. Percentage of patients with non-discordance and
those with discordance in fibrosis stage 1–2 (F1–2) vs. fibrosis
stage 3–4 (F3–4). Patients with F3–4 had the significantly higher
proportion of discordance than those with F1–2 (15.4% vs. 3.0%,
P,0.001).
doi:10.1371/journal.pone.0055759.g003
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diagnosis of uncomplicated cirrhosis [22] is an example in
which the FT and transient elastography are recommended as
the first-line noninvasive diagnostic tools for liver fibrosis. In
these guidelines, the fibrosis stage can be confirmed without LB
for a given patient if the respective fibrosis stage based on the
FT and transient elastography coincides, whereas LB is
recommended when there is a discordant result in fibrosis
staging between the FT and transient elastography. However,
although this diagnostic strategy is based mostly on accumulated
data from studies on CHC, it seems reasonable to combine the
FT with transient elastography for enhanced diagnostic accuracy
in assessing liver fibrosis in patients with CHB when we
Table 4. Comparison of patients with non-discordance and those with discordance.
Variables Patients with non-discordance Patients with discordance P value
(n=300, 90.9%) (n =30, 9.1%)
Clinical variables
Age (years) 44 (20–83) 43 (24–65) NS
Male gender 186 (62.0) 14 (46.7) NS
Body mass index (kg/m2) 23.5 (15.1–35.8) 23.1 (18.7–31.3) NS
Obesity ($30 kg/m2) 7 (2.3) 2 (6.7) NS
Aspartate aminotransferase (IU/L) 42 (16–385) 38 (12–70) NS
Alanine aminotransferase (IU/L) 49 (7–551) 55 (5–157) NS
Platelet count (109/L) 186 (80–489) 175 (100–283) NS
Fibrosis stage
F2–4 238 (79.3) 27 (90.0) NS
F3–4 137 (45.7) 25 (83.3) ,0.001
F4 63 (21.0) 14 (46.7) 0.012
Maximal activitya
A2–4 249 (83.0) 26 (86.7) NS
A3–4 107 (35.7) 9 (30.0) NS
A4 27 (9.0) 4 (13.3) NS
Maximal activitya grade was defined as the higher one between lobular and periportal activity.
Values are expressed as median (range) or no. (%).
doi:10.1371/journal.pone.0055759.t004
Table 5. Factors affecting discordance between FT and histology.
Univariate Multivariate
P value P value Adjusted odds ratio (95% confidence interval)
Clinical data
Age (years) NS
Male gender NS
Body mass index (kg/m2) NS
Aspartate aminotransferase (IU/L) NS
Alanine aminotransferase (IU/L) NS
Platelet count (109/L) NS
Fibrosis stage
F4 (vs. F1–3) 0.003
F3–4 (vs. F1–2) ,0.001 ,0.001 5.95 (2.22–15.96)
F2–4 (vs. F1) NS
Maximal activitya
A4 (vs. A1–3) NS
A3–4 (vs. A1–2) NS
A2–4 (vs. A1) NS
Maximal activitya grade was defined as the higher one between lobular and periportal activity.
NS, not significant.
doi:10.1371/journal.pone.0055759.t005
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consider the relatively lower performance of transient elasto-
graphy in patients with CHB than in those with CHC [4]. The
paucity of data regarding FT in patients with CHB and the
increase in cost of addition of the FT should also be addressed
in future studies.
This study has several strengths. First, a relatively large number
of subjects from three medical institutes were consecutively
enrolled, and the study population was homogenous and
representative of patients with CHB generally seen in clinical
practice. Second, because we recruited only patients who un-
derwent baseline blood tests on the same day as LB, potential bias
due to the gap between the two tests might have been prevented.
Third, by demonstrating predictors of discordance between the FT
and LB and proposing a rationale for combining several non-
invasive surrogates to enhance the diagnostic accuracy, our
findings will facilitate future studies that aim to propose a new
noninvasive diagnostic algorithm for liver fibrosis in Asian patients
with CHB.
However, we are also aware of several limitations of our
study. First, there were no subjects with F0 fibrosis. Because
three medical centers in this study are tertiary referral hospitals
and one of the largest medical centers in Korea, patients with
relatively more advanced disease are likely to be referred for
close follow-up. This might have resulted in a selection bias and
eventually a spectrum bias because the diagnostic performance
of a given noninvasive test tends to increase in general in
a cohort with high disease prevalence. Thus the diagnostic
performances of FT might have been overestimated in our
cohort. Therefore, another independent external validation
study in a population with minimal fibrotic burden should be
performed to provide more generalizable results in patients with
CHB-related chronic liver disease. Second, we could not
investigate the clinical role of the FT as a noninvasive
monitoring tool to predict dynamic changes in liver fibrosis
because a follow-up FT was not available. Third, although we
identified predictors of discordance, it is unclear whether the
long-term prognosis of patients with discordance differs from
that of patients with nondiscordance. In addition, whether we
should follow the results of the FT or LB to start treatment
intervention and predict the prognosis of a given patient is
unclear. Clarification of these issues requires longitudinal studies
using solid end-points such as hepatocellular carcinoma or liver-
related death.
In conclusion, advanced fibrosis stage (F3–4) showed a positive
correlation with discordance between LB and the FT in patients
with CHB. Furthermore, necroinflammation and ALT levels were
not factors predictive of accuracy. Future studies should focus on
methods of enhancing the diagnostic accuracy of the FT in clinical
practice.
This manuscript was checked by a professional editing service
(www.textcheck.com, certificate link: http://www.textcheck.com/
certificate/jNAqDE).
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